Export citation

Show simple item record

dc.contributor.authorJha, Akhilesh
dc.contributor.authorJarvis, Hannah
dc.contributor.authorFraser, Clementine
dc.contributor.authorOpenshaw, Peter
dc.date.accessioned2021-04-16T02:01:46Z
dc.date.available2021-04-16T02:01:46Z
dc.date.issued2016
dc.date.submitted2021-04-15T11:37:39Z
dc.identifierhttps://library.oapen.org/handle/20.500.12657/47857
dc.identifier.urihttps://directory.doabooks.org/handle/20.500.12854/64632
dc.description.abstractRespiratory syncytial virus (RSV) infection has an estimated global incidence of 33 million cases in children younger than 5 years, with 10% requiring hospital admission and up to 199,000 dying of the disease. There is growing evidence that severe infantile RSV bronchiolitis, a condition characterised by an inflammatory reaction to the virus, is associated with later childhood wheeze in some vulnerable children; however, a direct causal relationship with asthma has not yet been established. It is also increasingly recognised as a cause of morbidity and mortality in those with underlying airway disease, immunocompromise and frail elderly persons. Novel molecular based diagnostic tools are becoming established but treatment largely remains supportive, with palivizumab being the only licensed agent currently available for passive prophylaxis of selected pre-term infants. Whilst effective treatments remain elusive, there is optimism about the testing of novel antiviral drugs and the development of vaccines that may induce long-lasting immunity without the risk of disease augmentation.
dc.languageEnglish
dc.rightsopen access
dc.subject.classificationbic Book Industry Communication::M Medicine::MJ Clinical & internal medicine::MJC Diseases & disorders
dc.subject.otherviral lung disease, RSV, paediatric infections, bronchiolitis, mucosal immunity
dc.titleChapter 5 Respiratory Syncytial Virus
dc.typechapter
oapen.relation.isPublishedBye4ffdc34-97a1-4c5b-992f-04853e6f8983
virtual.oapen_relation_isPublishedBy.publisher_nameEuropean Respiratory Society
oapen.relation.isPartOfBookSARS, MERS and other Viral Lung Infections
virtual.oapen_relation_isPartOfBook.dc_titleSARS, MERS and other Viral Lung Infections
oapen.relation.isFundedByf6fcd900-36e2-4bc9-939e-ad820802e21f
virtual.oapen_relation_isFundedBy.grantor_nameWellcome Trust
oapen.relation.isFundedByd859fbd3-d884-4090-a0ec-baf821c9abfd
oapen.collectionWellcome
oapen.pages38
oapen.place.publicationSheffield
dc.relationisFundedByd859fbd3-d884-4090-a0ec-baf821c9abfd


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

open access
Except where otherwise noted, this item's license is described as open access